Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of pralsetinib in patients with RET-altered solid tumors
jRCT2031210144Phase 1Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pralsetinib in Nonhematologic neoplasms (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety, Pharmacokinetics and 1 more. Started Jul 2021; status: active, not recruiting.
02
Drugs
pralsetinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210144.